share_log

华东医药回应司美格鲁肽研发进展

Huadong Medicine responds to the development progress of Semaglutide.

Breakings ·  Jan 2 00:08

Regarding the research and commercialization progress of the company's Semaglutide, on January 2, Huadong Medicine stated to reporters that the company's Semaglutide injection is a product developed in cooperation with Chongqing Pijin. Currently, the diabetes indication has submitted a pre-BLA application and plans to submit a BLA application in the first quarter of this year, while the weight management indication has completed the first patient enrollment for Phase 3 clinical trials. The Semaglutide injection declared by Jiuyuan Gene is an independently developed product, and currently, there is no commercial cooperation intention between the company and Jiuyuan Gene for this product.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment